ASX:BDXPharmaceuticals, Biotechnology & Life SciencesBiotechnology
BCAL Diagnostics Ltd
$0.071
$0.004 (5.33%)
Day Range
$0.071 – $0.071
52 Week Range
$0.052 – $0.155
Volume
13.27K
Avg Volume (10D)
343.14K
Market Cap
$26.18M
Price Chart
Market Statistics
Open$0.071
Previous Close$0.075
Day High$0.071
Day Low$0.071
52 Week High$0.155
52 Week Low$0.052
Valuation
Market Cap26.18M
Shares Outstanding368.68M
Price to Book11.05
Trading Activity
Volume13.27K
Value Traded942.45
Bid$0.071 × 59,695
Ask$0.073 × 7,463
Performance
1 Day4.17%
5 Day-3.85%
13 Week-24.24%
52 Week15.38%
YTD-28.57%
Technical Indicators
RSI (14)45.87
50-Day SMA$0.077
200-Day SMA$0.092
Latest News
Biotechnology
BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring
BCAL Diagnostics launches BREASTEST Monitor—blood test to monitor post-treatment breast cancer recurrence; 91% sensitivity, 95% NPV.
Biotechnology
BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests
BCAL Diagnostics expands access to early cancer blood tests by embedding GP referral forms in major clinical software; launches EarlyDetection telehealth.
Biotechnology
BCAL Diagnostics Accelerates Avantect Rollout via Sonic Healthcare and Healius Partnerships
BCAL Diagnostics speeds Avantect rollout as Sonic Healthcare and Healius expand access to pancreatic/ovarian cancer tests nationwide.
Biotechnology
BCAL Diagnostics on Track for Australian Launch of Aventect Pancreatic and Ovarian Cancer Tests
BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.